DRAFT - NOT FOR PUBLICATION
Knuflium®
(knuf-li-um) / KNF‑α
Origin: African (Non-institutional lineage)
Status: For investigational use only
Pre‑release product information — Version 0.9.4
[[p0te pharmaceuticals]] • Confidential
IMPORTANT DISCLAIMER
This document represents a **preliminary draft** of product information for Knuflium®. It has not been approved by any regulatory authority and is not intended for public distribution, clinical use, or patient counseling.
All information contained herein is subject to change without notice and should be considered proprietary and confidential to [[p0te pharmaceuticals]].
Preliminary Observations (Phase I)
- Target Effect: Rapid onset of affiliative behavior and reduced social inhibition.
- Formulation Note (30/01/2026): Concentration increased to improve onset time. (Ref: B. Clarke)
- Safety Alert: Compound exhibits a pronounced dependence profile.
Do not discontinue abruptly. Subjects may experience erosion of emotional filtering.
Reference ID: PI‑KNF‑2026‑DRAFT
Revision Date: 05‑02‑2026
Supporting documentation